title: SMYD2 is highly expressed in pediatric acute lymphoblastic leukemia and constitutes a bad prognostic factor.
abstract: Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy. Although several clinical characteristics can be associated with worse prognosis, more robust biological markers still remains uncovered. SMYD2, a member of SMYD protein family, regulates the activity of several proteins through methylation. In this study, we performed quantitative real time PCR to compare the expression of SMYD2 in 83 pediatric ALL patients and non-neoplastic bone marrow samples (BMS). The study revealed that SMYD2 expression is altered in ALL BMS and its high expression was correlated with a bad prognosis. Moreover, we also revealed that SMYD2 expression level significantly decreases in patients that respond to chemotherapy treatment.
authors.affiliation: Laboratory of Molecular Pathology of Cancer, Faculty of Health Sciences, University of Brasilia, Brasilia, DF, Brazil; Cell Biology Department, University of Brasilia, Brasilia, DF, Brazil; Jose Alencar Children's Hospital of Brasilia, Brasilia, DF, Brazil.
authors.forename: Luis Henrique Toshihiro
authors.initials: LH
authors.lastname: Sakamoto
authors.affiliation: Laboratory of Genomic Sciences and Molecular Biotechnology, Catholic University of Brasilia, Brasilia, DF, Brazil.
authors.forename: Rosangela Vieira de
authors.initials: RV
authors.lastname: Andrade
authors.affiliation: Laboratory of Genomic Sciences and Molecular Biotechnology, Catholic University of Brasilia, Brasilia, DF, Brazil; Cell Biology Department, University of Brasilia, Brasilia, DF, Brazil.
authors.forename: Maria Sueli Soares
authors.initials: MS
authors.lastname: Felipe
authors.affiliation: Laboratory of Molecular Pathology of Cancer, Faculty of Health Sciences, University of Brasilia, Brasilia, DF, Brazil.
authors.forename: Andrea Barretto
authors.initials: AB
authors.lastname: Motoyama
authors.affiliation: Laboratory of Molecular Pathology of Cancer, Faculty of Health Sciences, University of Brasilia, Brasilia, DF, Brazil. Electronic address: pittella@unb.br.
authors.forename: Fabio
authors.initials: F
authors.lastname: Pittella Silva
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use; D054316:Biomarkers, Pharmacological; D014408:Biomarkers, Tumor / Q000235:genetics*; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D005260:Female; D015973:Gene Expression Regulation, Leukemic; D011495:Histone-Lysine N-Methyltransferase / Q000235:genetics*; D006801:Humans; D007223:Infant; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality*; D011379:Prognosis; D016019:Survival Analysis; D015854:Up-Regulation
chemical_list: D000970:Antineoplastic Agents; D054316:Biomarkers, Pharmacological; D014408:Biomarkers, Tumor; D011495:Histone-Lysine N-Methyltransferase; C512569:SMYD2 protein, human
keywords: Acute lymphoblastic leukemia; Childhood; Gene expression; Lysine methyltransferase; Prognosis; SMYD2